The genetic and molecular makeup of breast tumors holds clues to how a woman’s disease could progress, including the likelihood of it coming back after treatment, and in what time frame, according to a Cancer Research UK-funded study published this week in the journal Nature.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor regression in mouse models of small cell lung cancer (SCLC), suggesting a promising new approach for treating patients with this aggressive cancer.
Women with breast cancer who get newer genetic tests to estimate their risk of recurrence may not be any more anxious about their test results than their peers who get older tests that focus on fewer genes, a recent study suggested.
New research indicates that cancer survivors carry greater financial burdens related to medical debt payments and bills compared with individuals without a cancer history, with the greatest hardships in younger survivors.
Women may be able to go to their general practitioner (GP) to find out their risk of getting breast cancer and choose whether or not to be screened, if a new online calculator devised by British scientists is successful.